<DOC>
	<DOCNO>NCT00382161</DOCNO>
	<brief_summary>The purpose study determine effect fluvastatin penile arterial blood flow erectile function patient arteriogenic ED cardiovascular risk factor .</brief_summary>
	<brief_title>Improvement Erectile Dysfunction Fluvastatin Patients With Cardiovascular Risk Factors</brief_title>
	<detailed_description>Physiology erection mainly dependent endothelial NO-production consecutive activation guanylate-cyclase . Pleiotropic effect statins well know regard increase endothelial function . Thus , activation endothelial NO-synthase could raise activation guanylate-cyclase consecutive relaxation smooth muscle cell penile artery corpus cavernosum lead improvement erectile function . Therefore , statin suppose effective treatment erectile dysfunction , especially patient cardiovascular risk-factors underlie endothelial dysfunction . The effect fluvastatin penile blood-flow erectile function patient arteriogenic erectile dysfunction cardiovascular risk factor determine cross-over design . Patients either treat fluvastatin-sodium 80mg placebo 8 week . After wash-out 4 week , treatment switch ( placebo / fluvastatin-sodium ) . Penile blood flow measurement assessment erectile function IIEF-5-score KEED-score perform baseline , 8 week treatment , 4 week wash-out cross-over treatment ( 8 week ) .</detailed_description>
	<mesh_term>Erectile Dysfunction</mesh_term>
	<mesh_term>Fluvastatin</mesh_term>
	<criteria>male age &gt; 18 year arteriogenic erectile dysfunction ( penile blood flow peak systolic velocity &lt; 30cm/s , diastolic velocity &lt; 5cm/s ) two cardiovascular risk factor ( smoking , hypertension , hyperlipoproteinaemia , family history atherosclerosis , oral treat diabetes mellitus HbA1c &lt; 7 % ) stable course disease without expect change medical treatment next 3 month write informed consent statintreatment far know hypersensitivity anaphylaxis statin active liver disease unclear increase transaminase , cholestasis myopathy acute cardiovascular event ( myocardial infarction , stroke , PTCA , vascular surgery ) within 3 month randomization clinical sign heart failure reduce leave ventricular function current treatment lipid lower drug insulin dependent diabetes mellitus orally treat diabetes mellitus HbA1cvalue &gt; 6.9 % erectile dysfunction due hormone disorder know malignant tumor know disposition priapism patient morphological change penis ( i.e . deviation ) penisprosthesis current treatment anticoagulant current treatment immunosuppressive drug , phenytoin , erythromycin , gemfibrozil nicotinic acid derivates absence inability write informed consent</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2009</verification_date>
	<keyword>impotence</keyword>
	<keyword>erectile dysfunction</keyword>
	<keyword>cardiovascular risk factor</keyword>
	<keyword>statin</keyword>
</DOC>